Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7310662

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-752,997,000 JPY
-867,305,000 JPY
Depreciation
JPY
141,000 JPY
Interest and dividend income
-1,052,000 JPY
-536,000 JPY
Increase (decrease) in provision for retirement benefits
-1,109,000 JPY
-153,000 JPY
Interest expenses
2,185,000 JPY
1,781,000 JPY
Foreign exchange losses (gains)
-29,522,000 JPY
-34,696,000 JPY
Decrease (increase) in trade receivables
-32,206,000 JPY
JPY
Subtotal
-1,119,389,000 JPY
-446,855,000 JPY
Income taxes paid
-2,927,000 JPY
-2,923,000 JPY
Decrease (increase) in inventories
1,064,000 JPY
15,297,000 JPY
Net cash provided by (used in) operating activities
-1,124,153,000 JPY
-451,552,000 JPY
Other, net
-1,406,000 JPY
5,761,000 JPY
Interest and dividends received
25,000 JPY
243,000 JPY
Interest paid
-1,862,000 JPY
-2,017,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
JPY
-951,000 JPY
Proceeds from sale of property, plant and equipment
JPY
136,000 JPY
Net cash provided by (used in) investing activities
-1,184,000 JPY
-748,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
638,294,000 JPY
JPY
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Repayments of long-term borrowings
-44,440,000 JPY
-52,774,000 JPY
Net cash provided by (used in) financing activities
686,458,000 JPY
45,445,000 JPY
Repayments of lease liabilities
-4,929,000 JPY
-1,780,000 JPY
Effect of exchange rate change on cash and cash equivalents
23,573,000 JPY
30,994,000 JPY
Net increase (decrease) in cash and cash equivalents
-415,305,000 JPY
-375,860,000 JPY
Cash and cash equivalents
872,457,000 JPY
1,287,763,000 JPY
1,090,340,000 JPY
1,466,201,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.